SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

RV

Roberta Villa

@RobiVil · X

@RobertoBurioni @PiazzapulitaLA7 (A noi era stato offerto il dosaggio più basso, del tutto inutile secondo lo studio condotto dall'azienda stessa) https://t.co/KYYr4y1fsE

NS

Nathan Peiffer-Smadja

@nathanpsmad · X

Pour #bamlanivimab un essai randomisé encourageant chez 452 patients ambulatoires en phase précoce Réduction significative charge virale Hospitalisations : 1,6% (5/309) ds groupe bamlanivimab vs 6,3% (9/43) dans le groupe placebo mais non significatif https://t.co/znmIfzSoZd

NS

Nathan Peiffer-Smadja

@nathanpsmad · X

Il existe un faisceau d'arguments pour ces anticorps qui ont montré une efficacité pour prévenir infection #SARSCoV2 ou aggravation COVID si utilisation précoce https://t.co/f9iBqQe26K https://t.co/8o8tuAXk4Q https://t.co/1FU4LCnVUD https://t.co/5wn8h6wos1 https://t.co/WO6HzvgsfM

CT

Constantinos Tsioutis

@TsioutisC · X

Από άποψης ηθικής, γνωσιακής (sorry), αλλά και αυτοπροστασίας δεν είναι ορθό να αποφύγουμε ένα εμβόλιο και να προτιμήσουμε να νοσήσουμε και να λάβουμε θεραπεία!

B

Boniz

@bon1z · X

le notizie quelle belle SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/xpiFXh1v7P

I

ice9

@__ice9 · X

@ABsteward Using bamlanivimab (LY-CoV555) alone had rather mediocre performance in RCT-- https://t.co/2CP9S3xtcZ Adding etesevimab (LY-CoV016) seems to have helped considerably-- https://t.co/1vnWrgxWLh Combined: "reduced risk of COVID-19 hospitalizations and death by 70 percent"

M

MickeyTulip

@MickeyTulip · X

RT @MickeyTulip: #Coronavirus #Covid - Interpreting research: #SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NE…

CF

CSPCCM Fellowship

@CSPCCM · X

https://t.co/1dkrj1nHVd https://t.co/U42wH21dag https://t.co/JE44RtOJXx https://t.co/gsprNkQMJs

C

Clarissa

@clarissa_gmai · X

RT @RobiVil: @RobertoBurioni @PiazzapulitaLA7 (A noi era stato offerto il dosaggio più basso, del tutto inutile secondo lo studio condotto…

GM

Gio.Mallard

@MallardGio · X

RT @RobiVil: @RobertoBurioni @PiazzapulitaLA7 (A noi era stato offerto il dosaggio più basso, del tutto inutile secondo lo studio condotto…

EM

Emanuela Micucci

@EmMicucci · X

RT @RobiVil: @RobertoBurioni @PiazzapulitaLA7 (A noi era stato offerto il dosaggio più basso, del tutto inutile secondo lo studio condotto…

L

Luca

@folucar · X

RT @RobiVil: @RobertoBurioni @PiazzapulitaLA7 (A noi era stato offerto il dosaggio più basso, del tutto inutile secondo lo studio condotto…

RV

Roberta Villa

@RobiVil · X

@RobertoBurioni @PiazzapulitaLA7 (A noi era stato offerto il dosaggio più basso, del tutto inutile secondo lo studio condotto dall'azienda stessa) https://t.co/KYYr4y1fsE

SW

Syd Winarchist

@syd_winarchist · X

@Buscusriot @PeterMcCormack @Timcast https://t.co/wJ4nTGcgiQ https://t.co/W7WMy3H2ij https://t.co/sPXcdi7Jsg https://t.co/MkDeW0gsFy. Study (but don't trust) the science bro

WH

Wendy Hazen

@topproducer59 · X

https://t.co/lI0gXX3h1E

AC

Alejandro Castillo

@MediCasos · X

2. Anticuerpo LY-CoV555 para pacientes no hospitalizados con #covdi19 Conclusión: No, no sirve. https://t.co/vRJsTRNAdM

TF

Thomas Jefferson ID Fellowship

@jeffIDfellows · X

Congratulations to our very own Dr. Kathie Belden for her election as a distinguished Fellow of IDSA this year!! Faculty and fellows are not surprised in the least. @JeffersonGME @DrGregoryKane @TJUHospital Check out her publications online including https://t.co/OjnHFtO1VR

PQ

Pino Quintaliani

@Pqr9ap · X

BAMLAVINIMAB, CORTE DEI CONTI E GLI IPPOPOTAMI CHE VOLANO.   –    SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/X9nLtMSgu5

JS

John Smyth

@jonnynukeem · X

@Deus_Abscondis @MichaKobs @laurenmill3r93 @HectorReban @Qoppa999 ≥65 years or a BMI of ≥35 (at risk) LY-CoV555 reduced hospitalization 14.6% to 4.2%. https://t.co/wvMoDrBgKB

TJ

Tzippy Diskind صِپورة #JusticeForMalkiRoth

@zpyarom · X

RT @zpyarom: מחקרים על הטיפול: https://t.co/RoCgwNePmu וגם https://t.co/Mwhi2EpmAW למי שרוצה לחפש מידע נוסף באנגלית, הביטוי הוא monoclo…

TJ

Tzippy Diskind صِپورة #JusticeForMalkiRoth

@zpyarom · X

מחקרים על הטיפול: https://t.co/RoCgwNePmu וגם https://t.co/Mwhi2EpmAW למי שרוצה לחפש מידע נוסף באנגלית, הביטוי הוא monoclonal antibodies, או בקיצור MAbs.

AJ

André Jefremow

@anjefus · X

@docdailey @CMichaelGibson It wasn’t This https://t.co/v9Vk7a4Fo7 And here only secondary endpoint It wasn’t this Even though this study is more promising. Of course, we all treat patients regardless of whatever (e. g. Vaccination). Still, why do have the patients concerns about vaccinations with

A

afd44

@Afd44Ym · X

RT @nathanpsmad: Il existe un faisceau d'arguments pour ces anticorps qui ont montré une efficacité pour prévenir infection #SARSCoV2 ou ag…

RR

Renaloo, la voix des malades du rein

@Renalooo · X

RT @nathanpsmad: Il existe un faisceau d'arguments pour ces anticorps qui ont montré une efficacité pour prévenir infection #SARSCoV2 ou ag…

F

fontaineauxfees

@fontaineauxfees · X

RT @nathanpsmad: Il existe un faisceau d'arguments pour ces anticorps qui ont montré une efficacité pour prévenir infection #SARSCoV2 ou ag…

NS

Nathan Peiffer-Smadja

@nathanpsmad · X

Il existe un faisceau d'arguments pour ces anticorps qui ont montré une efficacité pour prévenir infection #SARSCoV2 ou aggravation COVID si utilisation précoce https://t.co/f9iBqQe26K https://t.co/8o8tuAXk4Q https://t.co/1FU4LCnVUD https://t.co/5wn8h6wos1 https://t.co/WO6HzvgsfM

ど

どこかの人

@mima09180402 · X

RT @carpe_diem0820: Eli Lillyによるウイルス中和モノクローナル抗体第2相治験の中間解析 3つの用量のうちの1つは、時間の経過とともにウイルス負荷の自然減少を促進するようだが、他の用量では11日目までの促進なし SARS-CoV-2 Neutrali…

TD

Thomas Davis

@TomDavisMD · X

Tell me @kerpen how these studies support the use of the mAb cocktail? Point to the confidence interval for a clinically meaningful endpoint that seals the deal. https://t.co/FWIZ1rCIzV https://t.co/tF2cTvuznY

SM

Sebastián González-Dambrauskas, MD

@sgdambrauskas · X

Más recomendados: https://t.co/lwXNHS6xqM https://t.co/WPHcYpu0SH https://t.co/jywuGtqSOB https://t.co/TV5rzCdHzG https://t.co/MaT6v7ID9m https://t.co/NWwXwwisz5

に

にゃあ

@kirikami · X

RT @shams_z: Some important papers on Ab Cocktails. 1. https://t.co/acPVCl3MZw 2. https://t.co/NfAXTia2lJ 3. https://t.co/BDdSskdAZF 4. ht…

B

BiotechObserver

@BiotechObserver · X

@TinFoilKazuya @TheRightMelissa Here is another one. Here is how you run a real clinical trial. https://t.co/9Ucmg2gJrf

IS

Isatou Sarr

@IsatouSarr4 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/3btwyWr5TQ

AL

Anatoly Lubarsky

@anatoly · X

@NashVolGuy @ScottAdamsSays @AndreasShrugged >>There are no other drugs for Covid during the timeframe<< https://t.co/NtgU1VU92Q https://t.co/Ly5z3GOxKX

SN

Shiva Narayanan

@shivn · X

@spkalantri BLAZE-1 did show those who had lower D7 VL had lower risk of hospitalization. Maybe suppressing VL before it triggers the immune inflammatory cascade is key in mitigating late outcomes when the virus is gone. https://t.co/j04SBe9aiJ https://t.co/ihTytlRKqb

RP

Robin Stephens, PhD

@stephrstephr · X

https://t.co/Thk35QWvvs

I

impressionist

@impressionist81 · X

@Kuts110 Lilly worked with AbCellera, the National Institute of Allergy and Infectious Diseases, and academic researchers to conduct experiments on the antibody candidate. The best candidate, they determined, was antibody No. 555: https://t.co/rNDQCDQ4Nc

NA

Nikkhlesh anand

@nikkhleshanand · X

RT @shams_z: Some important papers on Ab Cocktails. 1. https://t.co/acPVCl3MZw 2. https://t.co/NfAXTia2lJ 3. https://t.co/BDdSskdAZF 4. ht…

PS

Pigeon hate tweet account (STOPFUCKINGFEEDINGTHEM)

@psychedamygdala · X

RT @shams_z: Some important papers on Ab Cocktails. 1. https://t.co/acPVCl3MZw 2. https://t.co/NfAXTia2lJ 3. https://t.co/BDdSskdAZF 4. ht…

SC

Sudarshan Chate

@SudarshanChate2 · X

@VincentRK NIH study of Moderna at six months: https://t.co/T1N0HOevcV Bamlanivimab trial: https://t.co/v5GoWHqoxD J&J efficacy: https://t.co/aWTFvyfB5N Efficacy of Pfizer against B.1.351 in Qatar: https://t.co/imGJdTw53F Efficacy of AZ against B.1.351: https://t.co/GvERx3YMin

D医

Dr.医療株

@Dr41013079 · X

@ferbotto @ArgentinoHuman @PabloRichly Considering "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19" and "SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19", n=650 of PREPARE-IT 2 is fairly significant. Would you consider to announce its interim result?

IS

Isatou Sarr

@IsatouSarr4 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 https://t.co/lsE3zbuOsR

IS

Isatou Sarr

@IsatouSarr4 · X

https://t.co/uCvbJlpcHk

ST

Seth Trueger

@MDaware · X

@YFeyman @liverazzi sorry I mixed it up with remdesivir. BAM just shown to lower viral load and only in combo https://t.co/UXBYAP4MkE

R

Renitenz

@winkelcoaching · X

RT @Boschs_Owl: @Peter_Nater @IsolaOro @IsabelVillalon1 @hans_denkt Sie kennen dieses Produkt nicht? https://t.co/RCZxYzvjJ9

ΑA

αΦ APearlBird ©️

@APearlBird · X

@Peter_Nater @IsolaOro @IsabelVillalon1 @hans_denkt Sie kennen dieses Produkt nicht? https://t.co/RCZxYzvjJ9

ΑA

αΦ APearlBird ©️

@APearlBird · X

@hans_denkt @IsolaOro @IsabelVillalon1 „Gut möglich“ unterliegt dem, was die EMA wieder total verpennt: https://t.co/RCZxYzvjJ9

BJ

Ben Jones

@benjones1k · X

RT @EricTopol: It's a very important issue that is largely being ignored The other Phase 2 RCT: "The percentage of patients who had a Covid…

S

sivaprasad1984

@sivaprasad1984 · X

RT @epocrates: SARS-CoV-2 neutralizing antibody therapy shows promise. https://t.co/QbZiXmJG8q https://t.co/SPYjsIFQOX

DM

Daniel Montero

@ndanmontero · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 NEJM https://t.co/e2wOpaqyVx

GC

gerardo castrellon

@gcasol · X

RT @DoctorPanama: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/92rEycjd5c

SD

Stoic Doctor

@DoctorPanama · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/92rEycjd5c

I

INNOVACIONES

@foxmackalister · X

RT @noritren: @TheBruceIT @fo1984 @carbo_marco79 @RegLiguria @rep_genova @GenovaOnline @genova24it @matteomacor @ilsecoloxix @DomaniGiornal…

IC

Inkjet Connoisseur

@OttoKurect · X

@EngPhys @LillyPad They're being conservative but the answer is Yes, ~98% reduction of viral load, 5x reduction of hospitalization, increased survival etc: https://t.co/cxmvzxQ79R

DP

Damiano Protei

@DamianoProtei · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/DxzjoEKZmY

SL

Sébastien Lecan

@SebLecan · X

@DaCinal @CheckNewsfr Les essais ont besoin d'être poursuivis, avec de plus grandes cohortes. Mais, sans être un médicament miracle, les résultats sont tout de même encourageants, je trouve. https://t.co/JZuBcCf3w0 https://t.co/YQRnUVOu7c

S

Serab

@serab_ilane1 · X

RT @Dureresthard: @Celine_at_Paris Renseigne toi un peu sur le fond du problème plutôt, i.e. ce que dit la science (et la FDA US) du Bamlan…

KD

Knight Death Devil

@Dureresthard · X

@Celine_at_Paris Renseigne toi un peu sur le fond du problème plutôt, i.e. ce que dit la science (et la FDA US) du Bamlanivimab d'Eli Lilly avant de l'ouvrir à tort et à travers – et surtout en mode conspi. https://t.co/XAFf6GbuMS https://t.co/CPGwREMr8q

F

Flo

@falmnd · X

@Damkyan_Omega Pour l'instant on a des résultats intermédiaire de phase 2 : https://t.co/coEV98J4zE Par contre pourquoi on ne devrait pas les utiliser si ils ne marchent pas sur les variants SA/BR mais marchent avec le variant UK? Sachant qu'actuellement les variants SA/BR sont très minoritaire

AR

alex rubinsteyn

@iskander · X

@3DiMMUNE @LucreSnooker Why look at animal studies when we have positive trial results for outpatient treatment? https://t.co/tZG6enplbz

CC

Christian Combe

@ChristianCombe · X

@VTrillet_Lenoir @ansm @Sante_Gouv @olivierveran @CHUdeLyon @enmarchefr @Renaissance_UE Etonnant au vu des résultats https://t.co/Bz7T2IIpiw"the evaluation of the effect of LY-CoV555 therapy on patients’ symptoms at earlier time points during treatment (e.g., on day 3) showed a possible treatment effect, with no substantial differences observed among the 3 doses."

TO

Theriaque_officiel

@Theriaque_CNHIM · X

#SARSCoV2 #COVID19 Neutralizing Antibody LY-CoV555 #BAMLANIVIMAB in Outpatients with Covid-19 | NEJM https://t.co/rmgKmiQDza

DP

Dale Needham, MD, PhD

@DrDaleNeedham · X

RT @nickmmark: BLAZE1 phase2 of LyCOV555 was published @NEJM https://t.co/U4UYLif5oA It randomized 452 outpatients w/ COVID19 to 1 of 3 dos…

W

WesElyMD

@WesElyMD · X

RT @nickmmark: BLAZE1 phase2 of LyCOV555 was published @NEJM https://t.co/U4UYLif5oA It randomized 452 outpatients w/ COVID19 to 1 of 3 dos…

NM

Nick Mark MD

@nickmmark · X

BLAZE1 phase2 of LyCOV555 was published @NEJM https://t.co/U4UYLif5oA It randomized 452 outpatients w/ COVID19 to 1 of 3 doses of Ab vs placebo Treatment was associated w/ shorter duration of viremia & lower risk of hospitalization, w/o safety signals But... 3/ https://t.co/p9gwLHsR68

DN

Dr NotAgainstRaoult

@NoAgainstRaoult · X

RT @nathanpsmad: Pour #bamlanivimab un essai randomisé encourageant chez 452 patients ambulatoires en phase précoce Réduction significativ…

MN

maubois N .

@Sol121Nadia · X

RT @nathanpsmad: Pour #bamlanivimab un essai randomisé encourageant chez 452 patients ambulatoires en phase précoce Réduction significativ…

A

Arkhos94

@arkhos94 · X

RT @nathanpsmad: Pour #bamlanivimab un essai randomisé encourageant chez 452 patients ambulatoires en phase précoce Réduction significativ…

NS

Nathan Peiffer-Smadja

@nathanpsmad · X

Pour #bamlanivimab un essai randomisé encourageant chez 452 patients ambulatoires en phase précoce Réduction significative charge virale Hospitalisations : 1,6% (5/309) ds groupe bamlanivimab vs 6,3% (9/43) dans le groupe placebo mais non significatif https://t.co/znmIfzSoZd

PR

Paolo Ricci

@paolo27147205 · X

@giorgiogilestro @linomeschieri https://t.co/nBV5hpc1mZ https://t.co/MMpC2WKwbF

FM

Federico Di Matteo

@F_DiMatteo · X

@ivotnip @FPanunzi Che infatti è un’idiozia. A meno di non considerare NEJM l’equivalente del Lourdes Water Report https://t.co/edzBFE6AVV

MC

Marco Carbonaro

@carbo_marco79 · X

RT @noritren: @TheBruceIT @fo1984 @carbo_marco79 @RegLiguria @rep_genova @GenovaOnline @genova24it @matteomacor @ilsecoloxix @DomaniGiornal…

MR

manuel ricci

@noritren · X

@TheBruceIT @fo1984 @carbo_marco79 @RegLiguria @rep_genova @GenovaOnline @genova24it @matteomacor @ilsecoloxix @DomaniGiornale @Miti_Vigliero @GiovanniToti Io non ascolto palu, vado a leggere direttamente le fonti, cioè i risultati degli studi che lui cita. Se guarda lo studio principale su banlanivimab vedrà che non è molto entusiasmante, si parla di numeri bassi e sono esclusi i casi gravi. https://t.co/76HCWNAsDp

K

krzysztof

@KrzysztofKanios · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/stlVGZEIfg

LM

Lauren Westafer, DO MPH MS

@LWestafer · X

First up - Chen et al https://t.co/xoJnyDnOXb - This study came out first. It was a 4-arm RCT : 3 doses of bamlanivimab or placebo. Primary outcome: change in viral load on day 11. ⭐Not a patient-centered outcome. In fact, viral load (Ct) is of questionable significance (2/) https://t.co/LA2ndEW2cp

M

MB

@BaldrighiMattia · X

...⁦@ChimicoScettico⁩ https://t.co/AFmGF8HHDc

DM

Davide Tasselli MARIA

@DavideTasselli · X

RT @bon1z: le notizie quelle belle SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/xpiFXh1v7P

B

Boniz

@bon1z · X

le notizie quelle belle SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/xpiFXh1v7P

AC

Alistair Castagnoli

@alistair_cstgnl · X

#Hope https://t.co/FpSuPWHK2i

EC

Eduard Centeno

@segol60 · X

RT @alfonso_casi: Anticuerpo neutralizante SARS-CoV-2 LY-CoV555 en pacientes ambulatorios con Covid-19: en ensayo fase 2, una d las 3 dosis…

乙

乙です〜

@deep__wreck · X

SARS-CoV-2中和抗体の第二相、効いた感じのデータが出るのは1/3程度にとどまるのか。 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/BnGdLaikmS

AV

Alejandro Videla

@ajv67 · X

RT @alfonso_casi: Anticuerpo neutralizante SARS-CoV-2 LY-CoV555 en pacientes ambulatorios con Covid-19: en ensayo fase 2, una d las 3 dosis…

SJ

Salud juntos

@alfonso_casi · X

Anticuerpo neutralizante SARS-CoV-2 LY-CoV555 en pacientes ambulatorios con Covid-19: en ensayo fase 2, una d las 3 dosis del anticuerpo neutralizante acelera la reducción natural d la carga viral hasta el día 11, mientras que dosis adicionales no lo hacen https://t.co/Lb8G7rUZIc

JM

José Eduardo Riceto Loyola Junior, MD

@JEduardoJrMD · X

This drug from Lilly looks promising. It looks like a very interesting factorial design with a relevant sample size study, but I wish it had a clinical primary outcome. Nevertheless, it’s hard to dismiss the reduction in hospitalization. https://t.co/QfU6U8rVEa

CT

COVID Vaccine Tracker

@COVIDVaccineTr2 · X

2 leading pharma companies, Regeneration and Eli Lilly on the race to develop treatment & prophylaxis for COVID patients. Both are neutralizing antibodies or a cocktail of 2. Read up on the results of REGN-CoV2 and LY-CoV555 NEJM: https://t.co/4Rhx1T8oJr https://t.co/YactzdSArT

TL

Todd C. Lee

@DrToddLee · X

@ADAlthousePhD @statberry @BerryConsultant @stephensenn Comparing https://t.co/MkHE8hMVVd And https://t.co/vfK0qEaQ7h You can't really tell how the placebo are matched against mono doses compared to combo doses and it looks like there is maybe borrowing in both directions.

I

ice9

@__ice9 · X

RT @__ice9: @ABsteward Using bamlanivimab (LY-CoV555) alone had rather mediocre performance in RCT-- https://t.co/2CP9S3xtcZ Adding etese…

I

ice9

@__ice9 · X

@ABsteward Using bamlanivimab (LY-CoV555) alone had rather mediocre performance in RCT-- https://t.co/2CP9S3xtcZ Adding etesevimab (LY-CoV016) seems to have helped considerably-- https://t.co/1vnWrgxWLh Combined: "reduced risk of COVID-19 hospitalizations and death by 70 percent"

MP

My Online Pharmacist

@MyOnlinePharma1 · X

Here are more results from the BLAZE-1 trial for Eli-Lily's monoclonal antibody for the treatment of COVID19. Not very convincing. https://t.co/tQvP7fXwTC

BV

bhavin vasavada

@BhavinBVasavada · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM @nirajvasavada https://t.co/HP9bbzbesu

EG

Elliott Guerrero

@DoctorElliottBG · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 https://t.co/NNArAmdpNB

久K

久我 清 Kiyoshi KUGA

@kiyoshikuga · X

コロナ抗体薬 米イーライ・リリー　Eli Lilly LY-CoV555(バムラニビマブ) 効果80%　重篤無 https://t.co/KqFtoOKKOX 解説 https://t.co/JFvL1LrDPi 抗体薬 コロナ回復者血漿の抗体をコピーして作った医薬品 FDAはコロナ治療で緊急使用許可 https://t.co/M9ZnZah9ev 米政府は65万回分購入。13万円/回

にM

にゅろ, MD

@EBNeuro · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 https://t.co/ov24rj79PO Tweets: 875 COVID-19に対する中和抗体の第二相治験 ウイルス量低下を確認（当たり前すぎる） 重症度はわずかに低下（わずかに）

BM

BSWHealth.MED

@bswhealth_MED · X

Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization in COVID-19 patients. https://t.co/9D8MnZvUYz

DW

Dr. Christian Winter

@DrChristianWin1 · X

https://t.co/w4xZ6XsodP https://t.co/7CkgV8AFgP

يA

يزيد الرثيع|Yazed AlRuthia

@YazedAlruthia · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 https://t.co/uotOfNkU9h

CL

Chaim M Lebovits

@LebovitsM · X

@EMSwami @MDaware @ShohamTxID @Mvmnt_Is_Med https://t.co/4SciMgXUWl look at table 3( Hospitalizations) that’s where it showed the most benefit.

AM

Anand Swaminathan MD MPH

@EMSwami · X

Interestingly (but expected), did not show statistical difference in viral load reduction w/ any dose of bam monotherapy (contradicts findings of interim analysis https://t.co/caw6EEXdj7)

KA

Klinisk Farmakologisk Afdeling

@KlinFarmBBH · X

Bamlanivimab Phase 2 trial: 1 out of 3 doses (middle one!, 2800 mg) of nAB LY-CoV555 appeared to accelerate the natural decline in viral load over time. https://t.co/ujZdfBY3wm

B

BerriganKev

@BerriganKev · X

@cdube_sante Va falloir trouver une bonne raison pour justifier votre mauvaise raison d'avoir étiré la seconde dose à 90 jours, allant CONTRE les recommandations des experts Pfizer. C'EST VOTRE DÉCISION ! Après les covidiots : le ministridiot ! #polqc https://t.co/9RXwLtYA2z

M

Mushfiquzzaman

@Mushfiq_16 · X

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. https://t.co/Q4I1KYnbkn

F

ForensicPsyMD

@ForensicPsyMD · X

https://t.co/4w33LJymSI

O

OncoPapers

@sccancerres · X

RT @VivekSubbiah:

LN

Libert Nicolas

@dr_Libert_N · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/YNeqkDUhBV

HV

HAS-veille

@HAS_veille · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/YzGvrt9lv2

DV

Dr Jean Pierre Laroche #vacciné 6.0

@Echoraljpangio · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/QVt2tDnIxG

CT

Camilo J. Llamoza-Torres

@CamiloJT · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/Dw1hhk0hkO

SL

Sergyl LAFONT.

@sergyl_lafont · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/X2NeZLg9CX

L

LamazoneBlonde

@LamazoneBlonde · X

RT @TsioutisC: Από άποψης ηθικής, γνωσιακής (sorry), αλλά και αυτοπροστασίας δεν είναι ορθό να αποφύγουμε ένα εμβόλιο και να προτιμήσουμε ν…

MC

Mr. Columbo

@DetHolmes200 · X

RT @TsioutisC: Από άποψης ηθικής, γνωσιακής (sorry), αλλά και αυτοπροστασίας δεν είναι ορθό να αποφύγουμε ένα εμβόλιο και να προτιμήσουμε ν…

CT

Constantinos Tsioutis

@TsioutisC · X

Από άποψης ηθικής, γνωσιακής (sorry), αλλά και αυτοπροστασίας δεν είναι ορθό να αποφύγουμε ένα εμβόλιο και να προτιμήσουμε να νοσήσουμε και να λάβουμε θεραπεία!

DC

Daniel Coyne

@DrDanMO · X

Meanwhile we gear up to give this Ab earlier to high risk outpatients with mild-to moderate sx’s. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/ITpHAz5L8r

S

stellamar49

@stellamar49 · X

RT @marylinvalenti5: Un ensayo fase II observa que el uso de anticuerpo monoclonal LY CoV555 reduciria la carga viral y el porcentaje de ho…

MB

Martín Bazzino

@mbazzino · X

RT @marylinvalenti5: Un ensayo fase II observa que el uso de anticuerpo monoclonal LY CoV555 reduciria la carga viral y el porcentaje de ho…

LG

Luis Fernando Gasca

@fhergasca · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/nXUcR8oWU6 Otro estudio prometedor con anticuerpos monoclonales neutralizantes de SARS COV2 #COVID19

NB

Normax Biomed

@normaxbiomed · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/0A6TjoOVBI

BA

Bettina Ⓜ️arfetán

@bettinamarfetan · X

RT @marylinvalenti5: Un ensayo fase II observa que el uso de anticuerpo monoclonal LY CoV555 reduciria la carga viral y el porcentaje de ho…

MV

Marylín Valentin

@marylinvalenti5 · X

Un ensayo fase II observa que el uso de anticuerpo monoclonal LY CoV555 reduciria la carga viral y el porcentaje de hospitalización ⁦@ljr334⁩ https://t.co/6mOWP1TtCo #SARS_CoV_2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/GKS34wpvHq

SA

Syed Aqeel Abbas

@ZaidiAqeel · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19 https://t.co/E36Oq8nUp1

G

gooochin

@gooochin · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/fIcb5MI4Ed

F

fujikuro

@fujikurok · X

#COVID19 先日FDAに緊急承認されたイーライ・リリーのモノクロナール抗体治療薬バムラニビマブ（Bamlanivimab, LY-CoV555）の第2相臨床試験結果が10月末にNEJM論文で発表されています→ SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/wznCdmTaYR

LD

Loi Duong

@llduong21 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/EcRc3XjFRi

ما

مركز الأبحاث

@KFSHRC_Research · X

#SARS_CoV_2 Neutralizing Antibody LY-CoV555 in Outpatients with #Covid_19 https://t.co/S3Rt3kKqpw https://t.co/Aii7L3XEeu

AG

Antonio Guerrero

@guerreroespejo · X

La FDA de EE.UU. aprueba autorización de emergencia de tratamiento de la COVID-19 con anticuerpos frente a #SARSCoV2 de @LillyPad, del que el NEJM había publicado algunos datos SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #COVID19 | NEJM https://t.co/ZSvhfXqTES

AS

Ambily Sivadas

@ambilysivadas · X

RT @Abhinav_Jain_19: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #COVID19, eliminating >99.97% of viral RNA. #EliLilly…

AJ

Abhinav Jain

@Abhinav_Jain_19 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #COVID19, eliminating >99.97% of viral RNA. #EliLilly https://t.co/pWjJjlZJoR

NG

nasioulas georgios

@gnasioulas · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/hqGueg1Yi0

C

CoronaCentral

@coronacentralai · X

The second is: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. https://t.co/9S7CwamhCA

AB

Andre Bezerra

@andrebez · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/AA1HRiq1Lm

DF

Dacre Knight, MD, MS, FACP

@knidac · X

Not many treatments being studied for milder cases, but this one looks good. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 accelerates the natural decline in viral load over time | NEJM https://t.co/af1YxS3G2z

II

I am Immune

@DamanLangguth · X

Another treatment for COVID mostly not of use https://t.co/2uOcvjVWQg

B

Bowmedlib

@bowmedlib · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 https://t.co/dRy9eJKWcL

Y

Yaragraciano

@yaragracinha · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/SLhfFLvS1Z

DY

Don Young

@djyoungmd · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/2tZIq15aCg

RB

Renovatio Biomédica

@Renovatio2016 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/eWziv3JZDn

MC

MJA Editor in Chief

@MJA_Editor · X

RT @MJA_Editor: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #Covid "The percentage of patients who had a Covid-19–relate…

MT

Mihai Trofenciuc

@MihaiTrofenciuc · X

RT @ALEX_MISCHIE: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 @NEJM https://t.co/3FiJzpPHdO https://t.co/IB7O…

IR

Igor Rudan

@ProfIgorRudan · X

BLAZE-1 trial phase 2: one of three doses of neutralizing antibody LY-CoV555 accelerated the natural decline in viral load over time, whereas the other doses had not by day 11. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/HVpoZ8G5oc

M

MickeyTulip

@MickeyTulip · X

#Coronavirus #Covid - Interpreting research: #SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/cMH5xuzygS

M

MickeyTulip

@MickeyTulip · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/cMH5xuzygS

JM

john morley

@drjohnmorley · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/EtDCtqUFay

S

shivendra

@shivendraOnco · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/ualRKEFnFY

M

MUVBBvirtual

@MUVBBvirtual · X

MEDICINA INTERNA - Chwen et al - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in outpatients with Covid-19. - https://t.co/H6Mv0E4abt

C

CLAUDIA

@Claudia37Cleo · X

RT @ALEX_MISCHIE: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 @NEJM https://t.co/3FiJzpPHdO https://t.co/IB7O…

JC

joan carles

@juank1982 · X

RT @la_royo: #SARS_CoV_2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 @NEJM

CR

Cristina Royo

@la_royo · X

#SARS_CoV_2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 @NEJM

SM

stefano magionami

@magooswim · X

@alinatede Me sai di cose eh.... Leggi qua “ORIGINAL ARTICLE FROM NEJM SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Peter Chen and Others In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody .

PC

Président CNCH

@PresidentCNCH · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 @NEJM https://t.co/HKskQBqaDx @CNCHcollege @SFCardio @SFMU_MS

AM

ALEXANDRU MISCHIE

@ALEX_MISCHIE · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 @NEJM https://t.co/3FiJzpPHdO https://t.co/IB7OPKU6sC

DZ

Dra. Gabriela Zambrano

@gabizambranoMD · X

RT @LuisZuritaG: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/zbpYt44vHf

関

関西福祉大学　勝田吉彰　研究室

@tabibito12 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/4bvXWfpmGb

К

кєяιννу

@kerivvy · X

RT @MJA_Editor: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #Covid "The percentage of patients who had a Covid-19–relate…

MC

MJA Editor in Chief

@MJA_Editor · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #Covid "The percentage of patients who had a Covid-19–related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group". https://t.co/AFlxvo0um8

GP

Gema Tirado - Conde, MD, PhD

@BlossonSimonds · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/LOvwFo8dw6

N

NGR

@NGR69575822 · X

RT @DanielGriffinMD: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/pU2pnGEOva

SL

Sergio Lavandero

@sergiolavandero · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/nh5Ahu08Al

JL

JOSE LUIS

@TENTUCOYA · X

RT @LuisZuritaG: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/zbpYt44vHf

YL

Yaqub Latoo

@yaqublatoo · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/1zLL40509H

TH

Today's Hospitalist

@TodaysHospital · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 https://t.co/6ac1dw9mp7

EC

Eduard Centeno

@segol60 · X

Modest results without dose response relationship. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/3ANJreGYN9

PM

Prof. Dr. Attila Nemeth PhD MBA

@anemeth1965 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/aOWQ6lvGX7

LG

Luis Zurita G.

@LuisZuritaG · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/zbpYt44vHf

PP

Peter Persyn

@peter_persyn · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/IZbmu3zAv5

GZ

Giuseppe Biondi-Zoccai

@gbiondizoccai · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/3nt3f2ZOOb

ER

Elsa Gutiérrez R.

@elsaygr · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/zPZBK3klPs

CW

Colin Walsh

@happyspud1 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with #COVID19 | NEJM https://t.co/NuW0gAwiGh

IF

Inmaculada Flórez

@Inmafloralv · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM. NUEVAS ESPERANZAS DE TRATAMIENTO. https://t.co/79yFNNpyE3

MM

Martin Ibarrola MD

@elciudadanobv · X

Exceptional results. The bridge before vaccine? SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/5UxwChvZUK

HF

hawks__fan

@hawks__fan · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/gGlhUf96y8

JF

José M Morón Franco

@harroford · X

Un pasito más. Pacientes que recibieron anticuerpos neutralizantes ingresaron 4 veces menos que los que recibieron placebo. Ensayo fase II. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/OhSpbfn7oD

CC

Cristina Calvo

@CcalvoreyRITIP · X

Los anticuerpos neutralizantes en pacientes ambulatorios disminuyen la carga viral. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/PAkpWS9bDy

P

Pete

@123agua123 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM ⁦@clif_high⁩ https://t.co/Jy8tR4d6R7

T

theunretired

@theunretired · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/ZmD5tIPcFb

T

TrumpIsAPedo

@TrumpSuck5Putin · X

RT @LizSzabo: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/PGjIfQA6oa

LS

Liz Szabo

@LizSzabo · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/PGjIfQA6oa

JB

Jesus Ramirez-Bermudez

@JRBneuropsiq · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/8P4emZ4byR

ME

Medical Science and Technology #earlytreatments

@MedicalScitech · X

#SARSCoV2 Neutralizing Antibody #LYCoV555 in Outpatients with #COVID19 » https://t.co/QMwu0xI9Ki In this phase 2 trial, one of 3 doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in #viralload over time, whereas the other doses had not by day 11. https://t.co/3nA5gSratP

DR

Dr J Romero

@dr_romero1 · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/8OWHo5LuOI

AF

Andree Kurniawan MD, PhD, FINASIM

@a125ee · X

RT @Echoraljpangio: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/vHyK6czF0F

DV

Dr Jean Pierre Laroche #vacciné 6.0

@Echoraljpangio · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/vHyK6czF0F

AB

Adolfo Baloira

@AdolfoBaloira · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/09Hb98eS0c Datos moderadamente positivos pero quizá por debajo de lo esperado

NS

najwa syakira

@najwa__syakira · X

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM https://t.co/OpgbF16x6U

NU

Neglected Global Diseases Initiative at UBC

@NGDIUBC1 · X

RT @DavidPatrickMD: Early days. If interim findings extend to final analysis, our hunch that this BC-invented antibody treatment may work…

CR

COVID-19 Literature Situation Report

@covid19litrep · X

An interim analysis of an ongoing phase 2 randomized trial observed a significant decrease in viral load within 11 days among patients receiving a 2800 mg dose of the monoclonal antibody LY-CoV555. https://t.co/NO8hx1t9KS

さ

さくら

@Sakura_Med_DSci · X

モノクローナル抗体療法RCTの中間解析がNEJMに出てますね。 主要評価項目（ウィルス量）は全体では差がない（中用量のみ差がある）。副次の臨床スコアと入院率は差があった。 Discussionで、ウィルス量はサロゲートマーカーでしかない、と自虐的なことを書いてますが、、、

BJ

Bridget Jones^^

@Deer174229 · X

RT @MathieuMolimard: Perfusion d'anticorps neutralisants #COVID19 . https://t.co/wB1HWSLj3T Une piste à creuser https://t.co/khXJ7uT3yw

PM

Pr Mathieu Molimard

@MathieuMolimard · X

Perfusion d'anticorps neutralisants #COVID19 . https://t.co/wB1HWSLj3T Une piste à creuser https://t.co/khXJ7uT3yw

RC

Ronald M. Chavin

@rmchavin · X

10-28-2020: Here's a perfect example of how corrupt the results from clinical trials can be, if the researchers are paid off by governments, political parties, or evil elements of Big Pharma. LY-CoV555 performed very well against COVID-19 in this study: https://t.co/YYUrauEgfk